Adverse effects on hemostatic function of drugs used in hematologic malignancies

Anaadriana Zakarija, Hau C. Kwaan*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations


The adverse effects of drugs used in the treatment of hematologic malignancies are among the many factors contributing to the increased risk of both thrombosis and bleeding. These effects most often occur when combination of drugs are given. Some, such as L-asparaginase, result in both bleeding and thrombosis. Consideration must be given also to the bleeding or prothrombotic risk of the underlying hematologic disorder. The commonly used drugs with adverse effects on hemostasis include L-asparaginase, corticosteroids, inhibitors of vascular endothelial growth factor, gemtuzumab ozogamicin, thalidomide, and immunomodulatory derivatives of Thalidomide, and the hematopoietic growth factors. In addition, the syndrome of thrombotic microangiopathy may be brought on by several other drugs. Thus, a full understanding of these adverse effects is necessary in treating these disorders.

Original languageEnglish (US)
Pages (from-to)355-364
Number of pages10
JournalSeminars in thrombosis and hemostasis
Issue number4
StatePublished - Jun 2007


  • Growth factors
  • L-asparaginase
  • Leukemia
  • Myeloma
  • Thalidomide
  • Thrombosis

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Adverse effects on hemostatic function of drugs used in hematologic malignancies'. Together they form a unique fingerprint.

Cite this